Suchergebnisse - "Perrone, Francesco"

PubPharm (403)

11

Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021 : a meta-research study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Rossi, A. | Aimar, G. | Audisio, M. | +17

12

Brief Report : Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Piccirillo, M. | Chu, Q. | Bradbury, P. | +32

CommentIn: J Thorac Oncol. 2023 Jun;18(6):e67-e68. - PMID 37210188

13

Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)

enthalten in: Tumori | 2023

von Caminiti, C. | Bryce, J. | Riva, S. | +28

14

Effect of bevacizumab in advanced low grade serous ovarian cancer : Data from the MITO 22 trial

enthalten in: Gynecologic oncology | 2023

von Musacchio, L. | Turinetto, M. | Arenare, L. | +18

15

Pitfalls in Oncogeriatrics

enthalten in: Cancers | 2023

von Monfardini, S. | Perrone, F. | Balducci, L.

16

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

enthalten in: Journal of experimental & clinical cancer research : CR | 2023

von Forlani, L. | De Cecco, L. | Simeon, V. | +21

17

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

enthalten in: Journal of experimental & clinical cancer research | 2023

von Forlani, L. | De Cecco, L. | Simeon, V. | +21

18

Cancer in Transgender and Gender-Diverse Persons : A Review

enthalten in: JAMA oncology | 2023

von Leone, A. | Trapani, D. | Schabath, M. | +10

19

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3) : a multicentre, open-label, randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2023

von Pignata, S. | Scambia, G. | Schettino, C. | +128

CommentIn: Lancet Oncol. 2023 Mar;24(3):201-203. - PMID 37052963

20

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors

enthalten in: JAMA network open | 2023

von Goldstein, D. | Ginsberg, G. | Hofnung-Gabbay, D. | +9